Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Swiss (SMI) Clinical Research and Equipment Industry Analysis

UpdatedMar 21, 2026
DataAggregated Company Financials
Companies7
  • 7D-2.9%
  • 3M-9.5%
  • 1Y-16.0%
  • YTDn/a

Over the last 7 days, the Clinical Research and Equipment industry has dropped 2.9%, driven by a pullback from Lonza Group of 3.0%. However, the industry is down 16% over the past year. Earnings are forecast to grow by 19% annually.

Industry Valuation and Performance

Has the Swiss Clinical Research and Equipment Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Sat, 21 Mar 2026CHF 44.0bCHF 10.1bCHF 1.1b31.1x38.5x4.3x
Mon, 16 Feb 2026CHF 49.2bCHF 10.1bCHF 1.3b31.2x38.6x4.9x
Wed, 14 Jan 2026CHF 52.2bCHF 10.6bCHF 1.1b33.8x47.5x4.9x
Fri, 12 Dec 2025CHF 47.6bCHF 10.6bCHF 1.1b27.6x43.3x4.5x
Sun, 09 Nov 2025CHF 48.0bCHF 10.6bCHF 1.1b27.8x43.7x4.5x
Tue, 07 Oct 2025CHF 51.7bCHF 10.6bCHF 1.1b32.8x47x4.9x
Thu, 04 Sep 2025CHF 52.8bCHF 10.7bCHF 1.1b33.2x47.9x5x
Sat, 02 Aug 2025CHF 54.2bCHF 10.7bCHF 1.1b34.6x47.2x5.1x
Mon, 30 Jun 2025CHF 52.8bCHF 10.1bCHF 1.0b33.6x50.8x5.2x
Wed, 28 May 2025CHF 52.8bCHF 10.1bCHF 1.0b32x50.8x5.2x
Fri, 25 Apr 2025CHF 51.8bCHF 10.1bCHF 1.0b29.2x50.5x5.1x
Sun, 23 Mar 2025CHF 53.6bCHF 10.1bCHF 1.0b33.1x52.6x5.3x
Tue, 18 Feb 2025CHF 57.7bCHF 10.1bCHF 1.0b36.8x57.4x5.7x
Thu, 16 Jan 2025CHF 53.3bCHF 10.2bCHF 943.4m34.8x56.5x5.2x
Sat, 14 Dec 2024CHF 53.1bCHF 10.2bCHF 943.5m38.6x56.3x5.2x
Mon, 11 Nov 2024CHF 55.9bCHF 10.2bCHF 943.4m43.8x59.2x5.5x
Wed, 09 Oct 2024CHF 54.4bCHF 10.2bCHF 943.3m41.3x57.6x5.3x
Fri, 06 Sep 2024CHF 55.5bCHF 10.2bCHF 937.1m43.3x59.3x5.4x
Sun, 04 Aug 2024CHF 57.4bCHF 10.2bCHF 924.3m44.5x62.1x5.6x
Tue, 02 Jul 2024CHF 51.2bCHF 10.3bCHF 1.0b44.1x51.1x5x
Thu, 30 May 2024CHF 51.8bCHF 10.3bCHF 1.0b43.3x51.8x5x
Sat, 27 Apr 2024CHF 55.2bCHF 10.3bCHF 1.0b43.8x55.1x5.4x
Mon, 25 Mar 2024CHF 57.2bCHF 10.2bCHF 1.0b45.9x56.9x5.6x
Wed, 21 Feb 2024CHF 49.4bCHF 10.2bCHF 1.0b45.4x48.5x4.9x
Fri, 19 Jan 2024CHF 41.5bCHF 9.8bCHF 1.5b31.2x27.8x4.3x
Sun, 17 Dec 2023CHF 41.2bCHF 9.8bCHF 1.5b32.6x27.6x4.2x
Tue, 14 Nov 2023CHF 39.4bCHF 9.8bCHF 1.5b27.1x26.4x4x
Thu, 12 Oct 2023CHF 47.1bCHF 9.8bCHF 1.5b32x31.5x4.8x
Sat, 09 Sep 2023CHF 51.9bCHF 9.8bCHF 1.5b35.7x34.8x5.3x
Mon, 07 Aug 2023CHF 52.9bCHF 9.8bCHF 1.5b35.3x34.2x5.4x
Wed, 05 Jul 2023CHF 55.2bCHF 9.7bCHF 1.6b36.1x33.8x5.7x
Fri, 02 Jun 2023CHF 60.2bCHF 9.7bCHF 1.6b36.9x36.8x6.2x
Sun, 30 Apr 2023CHF 59.1bCHF 9.7bCHF 1.6b40.9x36.2x6.1x
Tue, 28 Mar 2023CHF 56.7bCHF 9.3bCHF 1.4b43.9x42x6.1x
Price to Earnings Ratio

42x


Total Market Cap: CHF 56.7bTotal Earnings: CHF 1.4bTotal Revenue: CHF 9.3bTotal Market Cap vs Earnings and Revenue0%0%0%
Swiss Clinical Research and Equipment Industry Price to Earnings3Y Average 45.9x202420252026
Current Industry PE
  • Investors are pessimistic on the Swiss Life Sciences Tools and Services industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 38.5x which is lower than its 3-year average PE of 45.9x.
  • The 3-year average PS ratio of 5.1x is higher than the industry's current PS ratio of 4.3x.
Past Earnings Growth
  • The earnings for companies in the Life Sciences Tools and Services industry have declined 5.4% per year over the last three years.
  • Meanwhile revenues for these companies have grown 2.9% per year.
  • This means that although more sales are being generated, either the cost of doing business or the level of investment back into businesses has increased, which has decreased profits.

Industry Comparison

How does Swiss Clinical Research and Equipment compare with similar industries?

CH Market-3.73%
Healthcare-4.87%
Life Sciences-2.86%
Clinical Research and Equipment-2.86%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
BANB Bachem HoldingCHF 61.852.5%
+CHF 110.1m		14.9%PE31.1x
PPGN PolyPeptide GroupCHF 24.601.2%
+CHF 9.9m		40.6%PS2.3x

Latest News

TECN
CHF 116.10
Tecan Group
7D
-4.4%
1Y
-32.9%

TECN: AI Lab Collaboration Will Support Forward Efficiency Gains And Earnings

The updated analyst price target for Tecan Group moves to CHF 166.50 from CHF 192.57, reflecting mixed Street views as some analysts trim targets while others highlight support from higher assumed revenue growth and a slightly lower future P/E multiple. Analyst Commentary Recent Street research on Tecan Group points to a split view, with some analysts trimming price targets and others turning more constructive on the shares.
BANB
CHF 61.85
Bachem Holding
7D
2.5%
1Y
14.9%

BANB: Future Execution On Growth Plans Will Support Higher CHF 80 Upside Potential

Analysts have nudged the consolidated price target for Bachem Holding to CHF 80, up CHF 5 from prior levels, citing updated assumptions for growth, profitability and a slightly lower P/E outlook that align with recent Street research moves. Analyst Commentary Street research on Bachem Holding has been mixed, with some analysts lifting price targets toward CHF 80 while others are more hesitant and keep targets closer to CHF 60.
PPGN
CHF 24.60
PolyPeptide Group
7D
1.2%
1Y
40.6%
SKAN
CHF 43.85
SKAN Group
7D
-9.7%
1Y
-39.3%

SKAN: Steady Assumptions And Higher Future P/E Will Support Further Upside

Analysts have slightly increased their price target for SKAN Group to CHF 71.00, reflecting modest adjustments to fair value, discount rate assumptions and projected P/E levels, while keeping revenue growth and profit margin expectations essentially unchanged. Valuation Changes Fair Value: Adjusted slightly from CHF 70.33 to CHF 71.00.
SFZN
CHF 73.10
Siegfried Holding
7D
-6.6%
1Y
-19.0%

SFZN: Modest Downgrade Will Still Support Future Upside Potential

Analysts have trimmed their price target for Siegfried Holding from CHF110.67 to CHF108.20, reflecting updated assumptions for discount rates, revenue growth, margins and future P/E following recent research, including a downgrade at RBC Capital. Analyst Commentary Bullish Takeaways Bullish analysts see the revised target price as still supportive of Siegfried Holding's current valuation, even after factoring in updated assumptions for discount rates and future P/E.
LONN
CHF 466.70
Lonza Group
7D
-3.0%
1Y
-17.9%
XLS
CHF 22.00
Xlife Sciences
7D
-8.3%
1Y
8.4%